study visits, HbA1c value could not be conﬁ  rmed by central laboratory, or fasting glucose >14·5 mmol/L on >4 days  in 1 week). †Sponsor judged that a patient needed to be withdrawn from the trial but the action was not taken by the investigator after repeated requests. ‡Patients identiﬁ  ed after the core 26-week period and excluded from the analysis. §One patient in each group entered the extension period, but did not receive a dose of study drug in this period; these two patients were excluded from the extension modiﬁ  ed intention-to-treat analysis. ¶Six patients in the exenatide group were given termination reasons by investigators, but completed the week 156 visit.